Center for Drugs and Biologics is recommending that Commissioner Young deny Upjohn's Aug. 4 request to reopen the record in the Depo-Provera hearing for additional evidence and to allow oral argument. In a letter to the commissioner, the center asserts that Upjohn's petition should be denied because the firm "has set forth no facts that establish the importance, and . . . even the relevance of the submissions that it proposes to be considered." Upjohn is requesting that the record be reopened to receive data from an interim report on a World Health Organization study of Depo-Provera, a new historical study on the association between Depo-Provera and breast cancer, a post-marketing surveillance study of Depo-Provera in the U.K., and a report by the Expert Committee on Reproductive Physiology.
You may also be interested in...
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.